Vonicog alfa
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder).[1][2][3] It is a recombinant von Willebrand factor.[1][2]
| Clinical data | |
|---|---|
| Trade names | Vonvendi, Veyvondi |
| Other names | BAX-111 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Hemostatic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C9712H15373N2737O3032S210 |
| Molar mass | 225725.54 g·mol−1 |
The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo.[1]
Vonicog alfa should not be used in the treatment of Hemophilia A.[2]
In the UK it is available only via a named patient access program.[4]
Vonicog alfa was approved for use in the United States in December 2015, and for use in the European Union in August 2018.[5][1][2][6] It was granted orphan drug designations in both the United States and the European Union.[2]
References
- "Vonvendi (von willebrand factor- recombinant kit". DailyMed. 13 February 2019. Retrieved 27 March 2020.
- "Veyvondi EPAR". European Medicines Agency (EMA). 20 September 2018. Retrieved 27 March 2020.
- "Veyvondi-epar product information" (PDF). European Medicines Agency.
- "Vonicog alfa". Specialist Pharmacy Service. 15 January 2020. Retrieved 27 March 2020.
- "Vonvendi". U.S. Food and Drug Administration (FDA). 9 May 2018. Archived from the original on 23 April 2019. Retrieved 15 April 2020.CS1 maint: unfit url (link)
- "Vonvendi". U.S. Food and Drug Administration (FDA). 13 April 2018. STN: 125577. Retrieved 27 March 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.